Telaprevir to boceprevir switch highlights lack of cross-reactivity

Clinical Infectious Diseases

Volumn 56, Issue 4, 2013, Pages 552-554

  Carlson, Amanda ^a   Gregorich, Zachery ^a   Striker, Rob ^a,b  

^a UNIVERSITY OF WISCONSIN SCHOOL OF MEDICINE AND PUBLIC HEALTH   (United States)

^b W S Middleton Veteran's Association   (United States)

Author keywords

boceprevir; duration; hepatitis C virus; telaprevir; toxicity

Indexed keywords

BOCEPREVIR; CORTISONE; DIPHENHYDRAMINE; PEGINTERFERON; RIBAVIRIN; TELAPREVIR;

ADULT; ANAL COMPLAINT; ARTICLE; CASE REPORT; CROSS REACTION; DRUG SUBSTITUTION; DRUG WITHDRAWAL; HEPATITIS C; HUMAN; HUMAN TISSUE; LIVER BIOPSY; MALE; OBESITY; PRIORITY JOURNAL; PRURITUS; RASH; RECTAL PAIN; RECTUM HEMORRHAGE; TREATMENT DURATION;

ANTIVIRAL AGENTS; CROSS REACTIONS; DRUG SUBSTITUTION; EOSINOPHILIA; EXANTHEMA; GENOTYPE; HEPACIVIRUS; HEPATITIS C, CHRONIC; HUMANS; MALE; MIDDLE AGED; OLIGOPEPTIDES; PROLINE; RNA, VIRAL; VIRAL LOAD;

EID: 84873028908     PISSN: 10584838     EISSN: 15376591     Source Type: Journal    
DOI: 10.1093/cid/cis960     Document Type: Article

References (12)

1. Strader DB, Wright T, Thomas DL, Seeff LB. Diagnosis, management, and treatment of hepatitis C. Hepatology 2004; 39:1147-71.
2. Ghany MG, Nelson DR, Strader DB, Thomas DL, Seeff LB. An update on treatment of genotype 1 chronic hepatitis C virus infection: 2011 practice guideline by the American Association for the Study of Liver Diseases. Hepatology 2011; 54:1433-44.
3. Butt AA, Kanwal F. Boceprevir and telaprevir in the management of hepatitis C virus-infected patients. Clin Infect Dis 2012; 54:96-104.
4. Montaudié H, Passeron T, Cardot-Leccia N, Sebbag N, Lacour JP. Drug rash with eosinophilia and systemic symptoms due to telaprevir. Dermatology (Basel) 2010; 221:303-5.
5. Frumin J, Gallagher JC. Allergic cross-sensitivity between penicillin, carbapenem, and monobactam antibiotics: what are the chances? Ann Pharmacother 2009; 43:304-15.
6. Guedj J, Perelson AS. Second-phase hepatitis C virus RNA decline during telaprevir-based therapy increases with drug effectiveness: implications for treatment duration. Hepatology 2011; 53:1801-8.
7. McHutchison JG, Everson GT, Gordon SC, et al. Telaprevir with peginterferon and ribavirin for chronic HCV genotype 1 infection. N Engl J Med 2009; 360:1827-38.
8. Incivek (Telaprevir manufacturer). A guide to help you assess and manage rash. 2012. Available at: http://www.incivek.com/hcp/assessand-manage-rash. Accessed 1 August 2012.
9. Picard O, Cacoub P. Dermatological adverse effects during genotype-1 hepatitis C treatment with the protease inhibitors telaprevir and boceprevir. Patient management. Clin Res Hepatol Gastroenterol 2012; 36:437-40.
10. Jacobson IM, McHutchison JG, Dusheiko G, et al. Telaprevir for previously untreated chronic hepatitis C virus infection. N Engl J Med 2011; 364:2405-16.
11. Kieffer TL, Sarrazin C, Miller JS, et al. Telaprevir and pegylated interferon-alpha-2a inhibit wild-type and resistant genotype 1 hepatitis C virus replication in patients. Hepatology 2007; 46:631-9.
12. Suzuki F, Suzuki Y, Akuta N, et al. Sustained virological response in a patient with chronic hepatitis C treated by monotherapy with the NS3-4A protease inhibitor telaprevir. J Clin Virol 2010; 47:76-8.